ProQR Therapeutics

122 articles with ProQR Therapeutics

• ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

  3/14/2023

  ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer®.

• ProQR to Present at Upcoming March 2023 Scientific and Industry Conferences

  3/7/2023

  ProQR Therapeutics N.V. announced several presentations highlighting the Company’s proprietary Axiomer® RNA editing technology platform at upcoming scientific and industry conferences.

• ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

  2/28/2023

  ProQR Therapeutics N.V. announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team.

• 

  Eli Lilly Expands RNA Editing Collaboration with ProQR Therapeutics

  12/22/2022

  Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration.

• Lilly and ProQR to Expand RNA Editing Collaboration

  12/22/2022

  Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines.

• ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

  12/22/2022

  ProQR Therapeutics N.V. today announced that ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST. 

• Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology

  12/22/2022

  Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines.

• ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

  11/14/2022

  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES Europe, that is being held November 16-18, 2022 in Vienna, Austria.

• ProQR Announces Third Quarter 2022 Operating and Financial Results

  11/9/2022

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, reported its financial and operating results for the third quarter ended September 30, 2022, and provided a business update.

• ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference

  11/3/2022

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, announced that Company management will participate in the Stifel 2022 Healthcare Conference.

• ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

  8/11/2022

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, provided an update on its ophthalmology programs following feedback from the European Medicines Agency related to sepofarsen and will now focus exclusively on its Axiomer® RNA-editing technology platform.

• ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

  6/1/2022

  ProQR Therapeutics N.V. announced that its 2022 Annual General Meeting of Shareholders will take place on Thursday, June 30, 2022 at 14:00 CET via videoconference.

• ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

  5/9/2022

  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S.

• ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

  4/26/2022

  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced several presentations at the 7th Annual Retinal Cell and Gene Therapy Innovation Summit being held Friday, April 29, 2022 and the Annual Meeting.

• ProQR to Participate in the Kempen Life Sciences Conference

  4/19/2022

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, announced that Company management will participate in the Kempen Life Sciences Conference on April 20, 2022.

• 

  ProQR to Cut 30% of Workforce, CSO Following Unexpected Trial Failure

  4/13/2022

  ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.

• ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

  4/13/2022

  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen program, following a comprehensive post-hoc analysis of the data from the Phase 2/3 Illuminate trial in people with CEP290-mediated Leber congenital amaurosis 10, or LCA10, a severe inherited retinal disease.

• ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

  4/4/2022

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced a presentation at the 3rd RNA Editing Summit held April 5-7 in Boston, MA, US.

• ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit - Mar 23, 2022

  3/23/2022

  ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29 as part of the RNA Therapeutics in Rare Diseases panel from 2:45-3:45pm EDT.

• Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for ProQR's Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials

  3/8/2022

  The Foundation Fighting Blindness is partnering with ProQR Therapeutics and InformedDNA® to accelerate patient identification and enrollment in clinical research for people with Usher syndrome or non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.